Skip Navigation
Find a Doctor
 
 
 
 

 

Search for
other physicians or researchers.

Find a Doctor
Photo of Dr. Julie Brahmer

Julie Renee Brahmer, MD

Associate Professor of Oncology
Female
Appointment Phone

410-955-8964

Primary Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Clinical Trials, Lung Cancer, Medical Oncology, Mesothelioma

Research Interests

Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma at SKCCC. She is in charge organizing the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. She is also a part of the oncology pain team headed by Dr. Stuart Grossman.

Biography

Dr. Brahmer''s research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer has published several papers in this area of research and is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation.

Languages

  • English

Memberships

ASCO, ACP, IASLC

Clinical Trial Keywords

  • Phase 1
  • mesothelioma
  • lung cancer

Additional Resources

Additional Resources +
  • Education +

    Training

    • University of Nebraska Medical Center - GME ( Omaha NE ) (1993)

    Residencies

    • The University of Utah/Internal Medicine ( Salt Lake City UT ) (1997)

    Fellowships

    • The Johns Hopkins Hospital/Oncology ( Baltimore MD ) (2000)

    Certifications

    • Medical Oncology, American Board of Internal Medicine (1999)
  • Research & Publications +

    Selected Publications

    Brock, M.V.; Hooker, C.M.; Engels, E.A.; Moore, R.D.; Gillison, M.L.; Alberg, A.J.; Keruly, J.C.; Yang, S.C.; Heitmiller, R.F.; Baylin, S.B.; Herman, J.G.; Brahmer, J.R. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55.

    Carducci, M.A.; Musib, L.; Kies, M.S.; Pili, R.; Truong, M.; Brahmer, J.R.; Cole, P.; Sullivan, R.; Riddle, J.; Schmidt, J.; Enas, N.; Sinha, V.; Thornton, D.E.; Herbst, R.S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006 Sep 1;24(25):4092-4099.

    Glazer, C.A.; Waldman, E.H.; Ansari-Lari, A.M.; Broussard, J.N.; Brahmer, J.; Tufano, R.P. Pathology quiz case 1. Metastatic mesothelioma involving the tongue. Arch Otolaryngol Head Neck Surg. 2006 Sep;132(9):1012, 1014-1015.

    Jimeno, A.; Kulesza, P.; Kincaid, E.; Bouaroud, N.; Chan, A.; Forastiere, A.; Brahmer, J.; Clark, D.P.; Hidalgo, M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res. 2006 Feb 15;66(4):2385-2390.

    Juergens, R.A.; Brahmer, J.R. Adjuvant treatment in non-small cell lung cancer: Where are we now? J Natl Compr Canc Netw. 2006 Jul;4(6):595-600.

    Li, J.; Brahmer, J.; Messersmith, W.; Hidalgo, M.; Baker, S.D. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs. 2006 Jul;24(4):291-297.

    Brahmer, J.R.; Ettinger, D.S. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology. 2007 May;12(3):320-325.

    Hann, C.L.; Brahmer, J.R. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Current treatment options in oncology. 2007 Feb;8(1):28-37.

    Higginson, D.S.; Brahmer, J.; Tufano, R.P.; Bajaj, G.K. Pleural mesothelioma metastatic to tongue. J Clin Oncol. 2007 May 20;25(15):2133-2135.

    Juergens, R.; Brahmer, J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep. 2007 Jul;9(4):255-264.

    Juergens, R.; Brahmer, J.; Ettinger, D. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-629.

    Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A.; Robey, R.W.; Bates, S.E.; Hidalgo, M.; Baker, S.D. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 2007 Mar;6(3):432-438.

    Madar, I.; Bencherif, B.; Lever, J.; Heitmiller, R.F.; Yang, S.C.; Brock, M.; Brahmer, J.; Ravert, H.; Dannals, R.; Frost, J.J. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med. 2007 Feb;48(2):207-213.

    Taguchi, F.; Solomon, B.; Gregorc, V.; Roder, H.; Gray, R.; Kasahara, K.; Nishio, M.; Brahmer, J.; Spreafico, A.; Ludovini, V.; Massion, P.P.; Dziadziuszko, R.; Schiller, J.; Grigorieva, J.; Tsypin, M.; Hunsucker, S.W.; Caprioli, R.; Duncan, M.W.; Hirsch, F.R.; Bunn, P.A., Jr.; Carbone, D.P. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007 Jun 6;99(11):838-846.
    Brahmer, J.R. Lung Cancer. In: Donehower, R.; Ettinger, D., editors. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

    Fathi, A.T.; Brahmer, J.R. Chemotherapy for advanced stage non-small cell lung cancer. Seminars in thoracic and cardiovascular surgery. 2008 Fall;20(3):210-216.

    Juergens, R.; Brahmer, J.R.; Spira, A.I. Effusions. 4th Edition ed, Clinical Oncology. New York, NY: Churchill-Livingstone; 2008.
    Messersmith, W.A.; Jimeno, A.; Ettinger, D.; Laheru, D.; Brahmer, J.; Lansey, D.; Khan, Y.; Donehower, R.C.; Elsayed, Y.; Zannikos, P.; Hidalgo, M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec;63(1):181-188.

    Novello, S.; Brahmer, J.R.; Siegfried, J. Gender Related Differences in Lung Cancer. In: al, P.e., editor. 4th Edition ed, Lung Cancer: Principles and Practices. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    Ramalingam, S.S.; Dahlberg, S.E.; Langer, C.J.; Gray, R.; Belani, C.P.; Brahmer, J.R.; Sandler, A.B.; Schiller, J.H.; Johnson, D.H. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-65.

    Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E.; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 1;26(7):1119-1127.

    Snyder, C.F.; Garrett-Mayer, E.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res. 2008 Jun;17(5):665-677.

    Socinski, M.A.; Novello, S.; Brahmer, J.R.; Rosell, R.; Sanchez, J.M.; Belani, C.P.; Govindan, R.; Atkins, J.N.; Gillenwater, H.H.; Pallares, C.; Tye, L.; Selaru, P.; Chao, R.C.; Scagliotti, G.V. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008 Feb 1;26(4):650-656.

    Guarino, M.J.; Schneider, C.J.; Hosford, M.D.; Brahmer, J.R.; Rudin, C.M.; Finkenstein, F.G.; Philip-Norton, R.E.; Lue, H.; Weber, M.R.; Ettinger, D.S. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.

    Riely, G.J.; Rizvi, N.A.; Kris, M.G.; Milton, D.T.; Solit, D.B.; Rosen, N.; Senturk, E.; Azzoli, C.G.; Brahmer, J.R.; Sirotnak, F.M.; Seshan, V.E.; Fogle, M.; Ginsberg, M.; Miller, V.A.; Rudin, C.M. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jan 10;27(2):264-270.

    Snyder, C.F.; Garrett-Mayer, E.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Concordance of cancer patients' function, symptoms, and supportive care needs. Qual Life Res. 2009 Oct;18(8):991-998.

    Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.

    Amann, J.M.; Lee, J.W.; Roder, H.; Brahmer, J.; Gonzalez, A.; Schiller, J.H.; Carbone, D.P. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010 Feb;5(2):169-178.

    Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-3175.

    Dahlberg, S.E.; Sandler, A.B.; Brahmer, J.R.; Schiller, J.H.; Johnson, D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010 Feb 20;28(6):949-954.
    Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.

    Snyder, C.F.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res. 2010 Aug;19(6):837-845.





    Brahmer, J. R., and D. S. Ettinger. 2007. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology 12:320-5.

    Brock, M. V., Hooker, C. M., Engels, E. A., Moore, R. D., Gillison, M. L., Alberg, A. J., Keruly, J. C., Yang, S. C., Heitmiller, R. F., Baylin, S. B., Herman, J. G. & Brahmer, J. R. (2006). Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43, 47-55.

    Brock, M. V., Hooker, C. M., Syphard, J. E., Westra, W., Xu, L., Alberg, A. J., Mason, D., Baylin, S. B., Herman, J. G., Yung, R. C., Brahmer, J., Rudin, C. M., Ettinger, D. S. & Yang, S. C. (2005). Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg 129, 64-72.

    Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., Enas, N., Sinha, V., Thornton, D. E. & Herbst, R. S. (2006). Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24, 4092-9.

    Fathi, A.T., and Brahmer, J.R. (2008). Chemotherapy for advanced stage non-small cell lung cancer. Seminars in thoracic and cardiovascular surgery 20, 210-216.

    Glazer, C. A., Waldman, E. H., Ansari-Lari, A. M., Broussard, J. N., Brahmer, J. & Tufano, R. P. (2006). Pathology quiz case 1. Metastatic mesothelioma involving the tongue. Arch Otolaryngol Head Neck Surg 132, 1012, 1014-5.

    Guarino, M.J., Schneider, C.J., Hosford, M.D., Brahmer, J.R., Rudin, C.M., Finkenstein, F.G., Philip-Norton, R.E., Lue, H., Weber, M.R., and Ettinger, D.S. (2008) Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 14, 119-124..

    Hann, C. L., and J. R. Brahmer. 2007. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?" Curr Treat Options Oncol 8:28-37.

    Higginson, D. S., J. Brahmer, R. P. Tufano, and G. K. Bajaj. 2007. Pleural mesothelioma metastatic to tongue. J Clin Oncol 25:2133-5.

    Jimeno, A., Kulesza, P., Kincaid, E., Bouaroud, N., Chan, A., Forastiere, A., Brahmer, J., Clark, D. P. & Hidalgo, M. (2006). C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66, 2385-90.

    Juergens, R. A. & Brahmer, J. R. (2005). Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future. Curr Oncol Rep 7, 248-54.

    Juergens, R., A. Spira, and J. R. Brahmer. In Press. Effusions. In M. A. Abeloff, J. O. Armitage, and J. E. Niederhuber (ed.), Clinical Oncology 4th Edition. Churchill Livingstone.

    Juergens, R., and J. Brahmer. 2007. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep 9:255-64.

    Juergens, R., Brahmer, J. & Ettinger, D. (2006). Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol.

    Juergens, R., Brahmer, J.R., and Spira, A.I. (2008). Effusions. In: Clinical Oncology, New York, NY: Churchill-Livingstone. In Press.

    Juergens, R., J. Brahmer, and D. Ettinger. 2007. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol 59:621-9.

    Li, J., Brahmer, J., Messersmith, W., Hidalgo, M. & Baker, S. D. (2006). Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24, 291-7.

    Li, J., G. Cusatis, J. Brahmer, A. Sparreboom, R. W. Robey, S. E. Bates, M. Hidalgo, and S. D. Baker. 2007. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432-8.

    Madar, I., B. Bencherif, J. Lever, R. F. Heitmiller, S. C. Yang, M. Brock, J. Brahmer, H. Ravert, R. Dannals, and J. J. Frost. 2007. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med 48:207-13.

    Messersmith, W.A., Jimeno, A., Ettinger, D., Laheru, D., Brahmer, J., Lansey, D., Khan, Y., Donehower, R.C., Elsayed, Y., Zannikos, P., and Hidalgo, M. (2008). Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 63, 181-188.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Upcoming Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-502-7159
    Appointment Phone: 410-955-8964
    Fax: 410-614-9334
    Location Map
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-583-2970
    Appointment Phone: 410-955-8964
    Fax: 410-614-9334
    Location Map

    Department/Division

    • Oncology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer